The contribution of epithelial-to-mesenchymal transitions (EMT) in both developmental and pathological conditions has been widely recognized and studied. In a parallel process, governed by a similar set of signaling and transcription factors, endothelial-to-mesenchymal transitions (EndoMT) contribute to heart valve formation and the generation of cancer-associated fibroblasts. During angiogenic sprouting, endothelial cells express many of the same genes and break down basement membrane; however, they retain intercellular junctions and migrate as a connected train of cells rather than as individual cells. This has been termed a partial endothelial-to-mesenchymal transition. A key regulatory check-point determines whether cells undergo a full or a partial epithelial-to-mesenchymal transitions/ endothelial-to-mesenchymal transition; however, very little is known about how this switch is controlled. Here we discuss these developmental/pathological pathways, with a particular focus on their role in vascular biology. (Arterioscler Thromb Vasc Biol. 2015;35:303-308.
M orphological changes in tissues are invariably associated with phenotypic changes in the cells that comprise them. Often these are limited to temporary changes in protein expression patterns, but more dramatic changes can also occur, during which cells undergo changes in transcriptional programs that lead to significant changes in morphology and function. One class of such changes is called the epithelialto-mesenchymal transition (EMT), and variants of traditional EMT include endothelial-to-mesenchymal transition (EndoMT) and partial EMT/EndoMT. Our focus will be to highlight the distinctions among the subsets, with an emphasis on angiogenesis as a unique example of a partial EndoMT.
Endothelial-to-Mesenchymal Transitions
Endothelial cells (EC) have many epithelial characteristics, including strong apical-basal polarity, the ability to form tubes, and the potential to undergo a transition to a mesenchymal-like cell (EndoMT). There are many reasons, therefore, to think that this process is related to EMT and may thus share some of the same pathways and effectors, including the key transcription factors Snail, Slug, Twist, Zeb1, and Zeb2, which we describe in detail further. There have been several excellent reviews published on EMT, [1] [2] [3] [4] and so we focus on EndoMT, with reference to EMT where clear overlaps exist. During embryogenesis, subsets of EC in the developing heart undergo EndoMT, acquire mesenchymal markers, invade the surrounding tissue, and form the valves and septa of the adult heart, 5 a process that involves transforming growth factor-β (TGFβ), bone morphogenetic protein, and Notch signaling pathways. 6, 7 These pathways converge on a complex network of transcription factors that includes HES, HEY1/2, Twist, and SOX9. 8, 9 Pathologically, EndoMT can be reactivated in the adult heart and has been shown to contribute to cardiac fibrosis, a characteristic common to most forms of heart failure. Using lineagetracing techniques, Kalluri's group demonstrated that 27% to 35% of fibroblasts present in fibrotic heart tissue were of EC origin, strongly suggesting a role for EndoMT in this process. Importantly, EndoMT was TGFβ1-dependent, whereas bone morphogenetic protein-7 preserved the EC phenotype and consequently reduced fibrosis. 10 Interestingly, however, a more recent study suggests that the accumulation of cardiac fibroblasts is not because of an EndoMT, but rather, the cells derive from a previously unrecognized fibroblast population, itself derived from ECs during development. 11 EndoMT has also been implicated as a source of fibroblasts in hypertrophic cardiomyopathy, 12 diabetes mellitus-induced cardiac fibrosis, 13 and chronic pulmonary hypertension, 14, 15 although these studies lacked definitive lineage-tracing analyses.
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There is also evidence supporting a role for EndoMT during both acute and chronic kidney injury. 16 In 3 distinct mouse models of chronic kidney disease, ≈30% to 50% of fibroblasts coexpressed the EC marker CD31 along with markers of myofibroblasts and fibroblasts, including fibroblast-specific protein-1 and α-smooth muscle actin. Lineage tracing experiments confirmed the EC origin of these cells. 16 More recent work has suggested that only ≈10% of the myofibroblasts present in kidney fibrosis derive from an EndoMT, whereas the remainder come from proliferation of local fibroblasts and differentiation from bone marrow cells. 17 Other studies, however, have suggested that these fibroblasts may be derived from pericytes. 18 It should be borne in mind, however, that these are all mouse studies and strain-specific differences are always a possibility. Other fibrotic diseases where EndoMT has been implicated as a source of fibroblasts/stromal cells include intestinal fibrosis 19 and scleroderma. 20, 21 In aggregate, these studies provide evidence that EndoMT likely provides a source of fibroblasts in both damaged heart and kidney (although the extent is unclear) and may function to facilitate tissue remodeling and fibrosis.
Finally, EndoMT also has a significant role to play in cancer. For example, Zeisberg et al, 22 using 2 different mouse models of cancer, demonstrated that EndoMT accounts for ≤40% of cancer-associated fibroblasts. A distinct population of fibroblasts coexpressed the EC marker CD31 along with either fibroblast-specific protein-1 or α-smooth muscle actin. Use of transgenic mice with irreversibly tagged EC revealed strikingly similar results-unique populations of fibroblasts coexpressing endothelial and mesenchymal markers. These data suggest that EndoMT is a significant source of cancerassociated fibroblasts in tumors. Remarkably, it has also been demonstrated that Twist overexpression in head and neck cancer cells can drive them into an EC phenotype. 23
Angiogenesis: A Partial EndoMT
When epithelial cells commit to a mesenchymal phenotype, the event is designated as a complete EMT. Partial EMT is also possible, and this occurs when ≥1 of the key characteristics of complete EMT are not exhibited, such as loss of cell-cell contact. For example, during re-epithelialization of cutaneous wounds, keratinocytes undergo a series of changes reminiscent of EMT, including loss of polarity, rearrangement of the actin cytoskeleton, alterations in cell-cell contacts, and breakdown of basement membrane; however, these cells retain some intercellular junctions and migrate as a cohesive cell sheet. 24 Similarly, during Madin-Darby canine kidney (MDCK) cell tubulogenesis, chains of epithelial cells migrate although again retaining intercellular junctions-a partial EMT driven by Slug activity. 25 Angiogenesis, the formation of new blood vessels from the preexisting vasculature, is essential during development and many normal physiological processes, but is also important in numerous pathological processes, including tumor growth. Interestingly, comparison of angiogenesis and EMT reveals several similarities. Among these, the tip cells that lead emerging sprouts lack apical-basal polarity, degrade both basement membrane and extracellular matrix and, by definition, are migratory. However, angiogenic EC do not usually separate from their neighbors, suggesting that angiogenesis may involve a partial EndoMT (Figure) . 26, 27 Although much is known about the growth factors, receptors, and signaling pathways that govern angiogenesis, there is still much to learn about transcriptional changes that regulate each phase of angiogenesis, including sprouting. Our laboratory has recently published preliminary evidence demonstrating that the transcription factors Snail (SNAI1 in human, Snai1 in mouse) and Slug (SNAI2/Snai2) are indeed expressed and regulated by angiogenic EC during in vitro angiogenesis. 26 We demonstrated that inhibition of Snail or Slug expression results in a reduced ability of angiogenic EC to invade and migrate through multiple extracellular matrix environments. Importantly, lentiviral-mediated re-expression of membrane type-1 matrix metalloproteinase (MT1-MMP) rescued the inability of EC lacking Slug to migrate. This finding, therefore, suggests that membrane type-1-MMP is a critical downstream target of Slug during angiogenesis. Importantly, we and others have observed increased expression of Snail and Slug in the vasculature of colon, breast, 28 and ovarian carcinoma. 29 It is interesting to speculate that the same factors that drive epithelial cells toward a mesenchymal, prometastatic phenotype may also drive EC toward a proangiogenic phenotype, which is also associated with metastasis. Key factors here may include vascular endothelial growth factor (VEGF), TGFβ, bone morphogenetic proteins, hepatocyte growth factor, and Wnts. The permanently activated phenotype of tumor vasculature may well reflect the chronic activation of the EndoMT process, driven by persistently elevated VEGF and a hypoxic environment, leading to excessive sprouting and a failure to settle back into the mature, stable phenotype associated with nontumor EC. It is possible therefore that drugs that target EMT/EndoMT, potentially through these pathways, may be doubly effective in slowing metastatic spread of epithelial tumors. Finally, we have preliminary data suggesting that Slug deficiency in mice leads both to impaired developmental and to pathological angiogenesis (Welch-Reardon KM, Wu N, Hughes CCW, unpublished data, 2014). In aggregate, these data clearly point to a role for the Snail family of transcription factors during angiogenesis. Furthermore, the findings that cell-cell contact is retained and expression of vascular endothelial-cadherin is not reduced are reminiscent of the partial EMT seen during keratinocyte migration in wound closure and during mammary gland or kidney epithelial cell tubule formation. 30 We therefore think that angiogenic sprouting may represent a partial EndoMT.
Signaling Pathways Governing EndoMT
EndoMT and EMT share many of the same regulators, with members of the TGFβ superfamily being arguably the most prominent players. TGFβ signaling through Smaddependent and independent pathways leads to direct transcriptional regulation of multiple genes, including several EMT/EndoMT-inducing transcription factors. 31 Expression of these transcription factors subsequently drives loss of cellcell adhesion by repression of epithelial/endothelial genes encoding junction proteins, regulation of cytoskeletal rearrangement, and increased expression and activity of both MT-MMPs and secreted MMPs. 32 Moreover, during EndoMT, upregulation of EC Slug by TGFβ and other growth factors results in increased migration and invasion into extracellular matrices of diverse composition, and this is due in part to the indirect activation of membrane type-1-MMP, MMP-2, and MMP-9. 26 Interestingly, nuclear Smads form multiprotein complexes with EMT/EndoMT-transcription factors, including Snail, Zeb1, and Zeb2, resulting in suppression or activation of promoters of epithelial (E-cadherin, Occludin, ZO-1) or mesenchymal (Vimentin, N-cadherin) genes, respectively. 4 TGFβ can also activate Smad-independent pathways, such as MAPK/ERK/JNK (mitogen-activated protein kinases/extracellular signal-regulated kinases/c-Jun N-terminal kinases), all of which are implicated in EndoMT. 31, 33, 34 Finally, a recent study has shown a requirement for PKCδ (protein kinase C) and c-Abl in mediating TGFβ-induced EndoMT in mouse pulmonary EC. 35 Aside from TGFβ, several other signaling pathways associated with EMT have also been reported to regulate EndoMT. The relationship between canonical Wnt signaling and the onset of EMT and metastasis is well established in many cancer models. In human prostate cancer, the expression and nuclear activity of β-catenin correlates with the level of hypoxia-induced factor 1 alpha and hypoxia-induced factor 1 alpha-induced EMT. 36 The degree of hypoxia-induced EMT can also be enhanced by Wnt3a-induced activation of β-catenin in hepatic carcinoma. 37 Furthermore, it has been demonstrated that canonical Wnt signaling stabilizes Slug expression through regulating glycogen synthase kinase 3-β phosphorylation and βTrcp-1-mediated ubiquitination, thereby inducing EMT in triple-negative breast cancer. 38 In contrast, the understanding of canonical Wnt signaling in EndoMT was mostly limited to developmental processes until recently. In an experimentally induced myocardial infarction model, Aisagbonhi et al, using lineage-tracing experiments, demonstrated that the canonical Wnt pathway is transiently activated in ECs, and this in turn leads to EndoMT. 39 More recently, the effect of Wnt7a and its antagonist Dkk-1 on EndoMT during arteriosclerosis was explored. In contrast to its effect on myofibroblasts, the activation of Wnt signaling through Wnt7b expression preserves the phenotype of ECs, whereas the expression of Dkk-1 promotes EndoMT. 40 Fibroblast growth factor (FGF) has been proposed as a gatekeeper of partial EndoMTs through its regulation of the let-7 miRNA, which normally acts to suppress TGFβ-induced EndoMT. 41 When FGF signaling is reduced in a murine model of transplant arteriopathy, in this case by inflammatory signals that downregulate the FGF receptor, let-7-mediated suppression of TGFβ signaling is relieved and EC undergo an EndoMT, leading to intimal fibrosis. Given that the sprouty genes, which regulate FGF receptor signaling, have previously been implicated in the regulation of EC sprouting, 42 it is tempting to speculate that they may be acting as a rheostat to fine-tune FGF signaling 43 and thereby control whether EC undergo a partial or full EndoMT in response to TGFβ signaling.
Notch activation is a well-known regulator of angiogenesis [44] [45] [46] [47] and is linked to both EMT and EndoMT events. The cleavage and nuclear translocation of the Notch intracellular domain can induce transcriptional alterations and hence a series of morphological and functional changes related to a mesenchymal transition. 48 Notch can suppress (or activate) gene expression directly or through upregulation of Snail and Slug in both epithelial cells and EC and, thus, initiate EMT and EndoMT in both developmental and pathological conditions. [49] [50] [51] Notch ligands can also be induced by TGFβ signaling to activate Notch receptors 52 and enhance EMT synergistically. 53 Blockage of either Jagged-1, or its downstream signaling target Hey-1, can attenuate TGFβ-induced EMT in mammary gland, kidney tubule, and epidermal epithelial cells. 50, 54 Notch and VEGF are both induced in the hypoxic tumor environment, and they work together to drive metastasis. On the one hand, interaction of Notch and hypoxiainduced factor pathways leads to increased stemness of cancer cells, self-renewal ability, and a complete EMT. 50, 55 On the other hand, hypoxia-dependent induction of VEGF expression
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February 2015 augments tumor angiogenesis, which provides increased opportunities for tumor cell intravasation. Finally, the crosstalk between Notch and VEGF pathways in the context of hypoxic tumors also promotes partial EndoMT in angiogenic tumor EC, leading to the formation of unstable, leaky vessels. 52 Altered vessel integrity and permeability correlates with enhanced tumor cell dissemination to distant sites. 56 Notch-mediated EMT/EndoMT is unusual, and somewhat paradoxical, as it is contact-dependent. Importantly, the ability of cells to retain intercellular adhesion complexes although migrating as a group is crucial to tubulogenesis. As described earlier, processes involving tubulogenesis, such as angiogenesis and kidney tubule formation, both require a partial EMT/ EndoMT, during which the participating cells temporarily lose apical-basal polarity and gain migratory capacity, but never fully acquire all mesenchymal phenotypes, nor completely lose cellular adhesion. Although other signaling pathways, such as TGFβ, hepatocyte growth factor, and FGF, are capable of promoting this process, it is intriguing to speculate that Notch activation, perhaps in conjunction with sprouty, is a crucial determinant of a partial versus full EMT/EndoMT.
Aside from the major signaling pathways discussed earlier, miRNA, epigenetic regulation, and histone modification have also recently emerged as regulators of EMT 30, 32 and may also have a role in EndoMT. 41 These alterations control the expression level of the Snail/Slug, ZEB, and Twist families of tran scription factors, and these in turn feed back to affect either the expression of the miRNA or histone-modifying enzymes, or their activity. 30, 32 Clearly, the relationship(s) between the master regulators governing EMT/EndoMT are extremely complex. 4, 31 
Transcription Factor Interactions Governing EndoMT
Snail (SNAI1 in human, Snai1 in mouse), Slug (SNAI2/Snai2), Zeb1 (ZEB1/Zeb1), Zeb2 (ZEB2/Zeb2), and Twist (TWIST1/ Twist1) have been identified as the key transcriptional regulators of EMTs and EndoMTs. A shared function of these proteins is their ability to repress the transcription of epithelial-cadherin (E-cadherin); however, numerous studies have demonstrated that they have overlapping but nonredundant roles in EMT and tumor progression. In human carcinomas, it is generally accepted that Snail plays a major role in inducing EMT, whereas Zeb1/2 and Twist are mainly involved in maintaining the invasive mesenchymal phenotype. 32 However, our recent study on EndoMT suggests that at least in the case of sprouting angiogenesis, Slug is the primary initiator of this process, whereas the induction of Snail occurs at a much later time. 26 It is therefore unclear if each of these transcription factors has a distinct and specific role during EMT/EndoMT or if they rather act in symphony to promote a mesenchymal phenotype. Accumulating evidence from studies observing their expression patterns and their ability to regulate each other has begun to reveal a nonlinear map that suggests that these transcription factors mostly act in concert. For example, Snail can upregulate Zeb1 and Zeb2 in oral squamous carcinoma and, at the same time, negatively regulate its own expression through direct promoter binding. 57, 58 Moreover, Slug indirectly upregulates Snail through epithelial growth factor or hepatocyte growth factor signaling, thereby promoting mammary gland branching morphogenesis. 59 Slug can also activate Zeb1 and its own expression through direct transcriptional regulation. 60, 61 In addition, many have shown that Twist1 can regulate the expression level of Snail and Slug by either directly influencing transcription 62, 63 or through post-translational regulation via the NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells)/glycogen synthase kinase 3-β axis. 64
Dynamic Functions of EndoMT Transcriptional Regulators
The master regulators of EMT mediate repression of E-cadherin expression, and this is often described as the hallmark of EMT. However, several recent studies show that in both in vitro and in vivo models, EMT master regulators can induce EMT/EndoMTlike phenotypes in cells without complete loss of membrane E-cadherin-a partial EMT. Similarly, we observed that overexpression of Slug in EC promotes EC sprouting, a process suggestive of a partial EndoMT, without altering the mRNA levels or surface expression of vascular endothelial-cadherin, the EC equivalent of E-cadherin. 26 Interestingly, Leroy et al others have shown that Slug upregulation prevents apoptosis and promotes cell proliferation through p53, 25 2 processes associated with angiogenic sprouting. The induction of Twist alone, perhaps surprisingly, is sufficient to induce single cell dissemination/local invasion without the loss of epithelial identity, and moreover, E-cadherin expression is required for this process. 65 Conversely, the deletion of E-cadherin alone is not sufficient to induce EMT. Indeed, in the absence of E-cadherin, and despite a reduction in multiple classes of junction proteins, epithelial cells are still able to invade an extracellular matrix as a chain rather than single cells. 65 Collectively, these data suggest that master regulators of EMT and EndoMT serve more functions than simply acting as repressors of the epithelial/endothelial phenotype.
Remaining Questions and Perspectives
Our knowledge of the mechanisms underlying EMT and EndoMT is rapidly advancing; however, there are still several critical questions that have to be answered, including the following:
• Are Snail, Slug, Twist, Zeb1, and Zeb2 all required for an EndoMT? • Do these genes work sequentially, in parallel or in feedback loops? • What regulates expression of EndoMT-promoting transcription factors? • What are the target genes for EndoMT transcription factors? • What controls whether cells undergo a full or partial En-doMT? • How is vascular endothelial-cadherin protected from downregulation in partial EndoMT? • Are there fundamental differences between EMT and En-doMT or are the basic mechanisms identical? • Do the same factors that promote EMT in cancer promote EndoMT in angiogenic EC? • How does EndoMT contribute to progression of diseases, such as cancer, arteriosclerosis, and fibrosis? • Are there fundamental differences between pathological EndoMT and developmental EndoMT?
• Can EndoMT be targeted therapeutically in cancer and other diseases involving pathological angiogenesis?
Answers to these questions have the potential to fundamentally affect how we target pathological angiogenesis.
